EP 321 James Fadiman and Jordan Gruber on Microdosing Psychedelics

Microdosing psychedelics like LSD and psilocybin at sub-threshold levels offers significant potential for improving mental and physical health, performance, and cognitive flexibility. By operating below the threshold of hallucinogenic effects, these substances facilitate neuroplasticity and systemic anti-inflammatory benefits, aiding recovery from conditions like treatment-resistant depression, long COVID, Lyme disease, and autism. Unlike conventional pharmaceuticals that target specific symptoms, microdosing supports overall biological functioning, often yielding positive results where traditional medicine fails. Structured protocols, such as the Fadiman Protocol, prioritize conservative dosing and periodic breaks to prevent tolerance and allow the body to integrate improvements. While legal barriers persist, global adoption continues to expand through community-driven, real-world evidence, challenging the rigid reliance on double-blind clinical trials for substances that are inherently difficult to blind.